AAPL 179.06 +0.32 (+0.18%)MSFT 126.11 +0.03 (+0.02%)FB 181.06 +0.03 (+0.02%)ZNGA 6.06 -0.02 (-0.33%)NVDA 144.95 -0.07 (-0.05%)WBA 51.77 +0.01 (+0.02%)GOOG 1133.33 +0.71 (+0.06%)PIH 5.61 -0.09 (-1.58%)
AAPL 179.06 +0.32 (+0.18%)MSFT 126.11 +0.03 (+0.02%)FB 181.06 +0.03 (+0.02%)ZNGA 6.06 -0.02 (-0.33%)NVDA 144.95 -0.07 (-0.05%)WBA 51.77 +0.01 (+0.02%)GOOG 1133.33 +0.71 (+0.06%)PIH 5.61 -0.09 (-1.58%)

Financial Summary CRSP Quote CRISPR Ther

CRISPR Therapeutics AG Quote

CRISPR Therapeu (CRSP)

37.02 0.1 Healthcare
Stock Performance rating :
Recommendation :
Strong Sell
Score :
D+
Symbol CRSP
Price 37.02
Beta 3.08
Vol Avg 1.15 M
Mkt cap 1.78 B
Shares 20
Last Div Not Available
Div Yield 0.00%
DCF Unlevered 0.00
DCF Levered 0.00
ROE 179.31% Strong Buy
ROA -32.70% Strong Sell
Operating Margin -Infinity% Strong Sell
Debt/Equity -651.72% Strong Sell
P/E -28.48 Strong Sell
P/B -25.53 Strong Sell
All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 0 0 0 0 0
COGS 0 0 0 0 0
GrossProfit 0 0 0 5 41
Depreciation (included in COGS) 0 0 0 0 0
StockBasedCompe (included in COGS) 0 1 4 11 19
ResearchAndDeve 0 2 13 42 70
SalesGeneralAnd 0 5 13 31 36
OperatingIncome 0 -7 -26 -68 -65
InterestExpense 0 0 0 8 0
OtherIncome 0 0 0 53 -2
IncomeBeforeTax 0 -7 -26 -23 -67
ProvisionForInc 0 0 0 0 0
NetIncome 0 -6 -26 -23 -68
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 0 1 156 316 240
ShortTermInvest 0 0 0 0 0
Cash 0 1 156 0 0
AccountReceivab 0 0 0 0 0
Inventories 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
OtherCurrentAss 0 0 0 1 0
TotalCurrentAss 0 1 157 320 248
PPE 0 0 1 22 23
AccumulatedDepr 0 0 0 -1 -4
NetPPE 0 0 1 21 19
EquityAndOtherI 0 0 0 0 0
Goodwill 0 0 0 0 0
IntangibleAsset 0 1 0 0 0
OtherLTAssets 0 0 1 3 4
TotalNonCurrent 0 1 3 25 23
TotalAssets 0 2 159 345 271
ShortTermDebt 0 0 0 0 0
AccountsPayable 0 0 2 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 0 2 8 0 0
DeferredRevenue 0 0 75 78 57
OtherCurrentLia 0 0 0 1 1
TotalCurrentLia 0 2 10 22 15
Debt 0 0 38 0 0
DeferredTaxesLi 0 0 0 0 0
DeferredRevenue 0 0 0 0 0
OtherLTLiabilit 0 6 65 12 12
TotalNonCurrent 0 6 178 90 69
TotalLiabilitie 0 9 189 112 84
CommonStock 0 0 0 1 1
AdditionalPaidI 0 1 5 289 312
RetainedEarning 0 -8 -34 -57 -125
AccumulatedOthe 0 0 0 0 0
TotalStockholde 0 -7 -29 233 188
TotalLiabilitie 0 2 159 345 271
Cash Flow Statement
Year 20142015201620172018
NetIncome 0 -6 -26 -23 -68
Depreciation 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
StockBasedCompe 0 1 4 11 19
AccountsReceiva 0 0 0 -3 1
InventoryCS 0 0 0 0 0
AccountsPayable 0 0 0 0 0
OtherWorkingCap 0 2 82 6 -22
OtherNonCashIte 0 0 0 -46 2
NetCashProvided 0 -5 59 -55 -70
InvestmentsInPP 0 0 -1 -3 -8
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve 0 0 0 0 0
SalesMaturities 0 0 0 0 0
PurchasesOfInta 0 0 0 0 0
OtherInvestingA 0 0 0 35 0
NetCashUsedForI 0 0 -1 32 -8
DebtIssued 0 0 38 35 0
DebtRepayment 0 0 0 0 0
CommonStockIssu 0 0 0 89 0
CommonStockRepu 0 0 0 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 0 0 0 -2 3
NetCashProvided 0 5 97 183 3
NetChangeInCash 0 1 155 160 -76
CashAtBeginning 0 0 1 156 316
CashAtEndOfPeri 0 1 156 316 240
Retained Earnings
Year 20142015201620172018
RetainedEarning -----8
NetIncome ----6-26
StockDividend ---1452
DividendPaid -----
RetainedEarning ----8-34
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE -----
DeprAnnual 0----
CapitalExpendit 00001
NetPPE ----1
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0---1
Amortization 0----
NewPurchases 0--1-1
intAndGW ---1-
Company Profile

CEO

Samarth Kulkarni

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ Global Market

Description

CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.